Many ovarian cancer patients denied by-the-book care, study says

March 12, 2013 by Kathleen Doheny, Healthday Reporter in Cancer

Many ovarian cancer patients denied by-the-book care, study says

Result: They're 30 percent more likely to die over five-year span, researchers find.

(HealthDay)—Nearly two-thirds of ovarian cancer patients don't receive recommended treatment that could extend their lives, U.S. researchers have found.

For patients who didn't get care that follows the National Comprehensive Cancer Network (NCCN) , the risk of dying within five years of follow-up was 30 percent greater compared to women who got recommended , said researcher Dr. Robert Bristow, director of at the School of Medicine of the University of California, Irvine.

Low-volume hospitals—those that treat few cases of ovarian cancer—are less likely than larger hospitals to follow the established recommendations for ovarian cancer, according to the study.

The findings lend support to the guidelines, Bristow said.

Women facing treatment for ovarian cancer, he said, should ask their doctor: "How many ovarian do you treat a year?" If the answer is two, "You probably don't want to be one of those patients," Bristow said.

Each year, about 22,000 new cases of ovarian cancer are diagnosed in the United States, and more than 15,000 women die of it, according to the .

For the study, Bristow and his colleagues analyzed the treatment and results for more than 13,000 women with ovarian cancer, using data reported to the California Cancer Registry from 1999 through 2006.

That time period was selected because there was no overall change in treatment approaches during those years, Bristow said. Such changes might have affected the results, scheduled for presentation Monday at the Society of Gynecologic Oncology annual meeting in Los Angeles.

Half the women studied were younger than 61, and the majority, 70 percent, had advanced cancer. First, the researchers looked to see how many women got treatment as recommended by the cancer network. The network is an alliance of 21 cancer centers that develops treatment guidelines.

Only 4,952, or 37 percent, got the recommended treatment.

Bristow's team looked at patient-related and health care system factors that might predict better adherence to treatment guidelines. They found the number of cases of ovarian cancer treated by the hospital and by individual doctors played a role.

"The high-volume hospitals, which did 20 or more cases a year, and high-volume physicians, which did 10 or more a year, were significantly more likely to administer treatment that was adherent to NCCN guidelines," Bristow said.

But even high-volume hospitals weren't always in compliance with the guidelines. High-volume hospitals delivered appropriate care 51 percent of the time, compared to 34 percent by low-volume facilities. High-volume doctors delivered appropriate care 48 percent of the time, compared to 34 percent by low-volume doctors.

Most of the women got care at low-volume facilities by doctors with little experience treating .

Treatments include surgery and chemotherapy. In many cases, doctors provided some of the recommended care—either chemo or surgery—but not both, Bristow found.

In some cases, Bristow said, it's not possible to follow guidelines. For instance, an elderly women with other health issues, such as congestive heart failure, probably couldn't tolerate chemotherapy, he said.

A California-based expert, Dr. Mark Wakabayashi, said the finding ''echoes previous findings and my own clinical practice." Wakabayashi, division chief of gynecologic at the City of Hope Comprehensive Cancer Center, said he has treated many women whose previous cancer care did not follow these guidelines.

Compared to the national norms, survival statistics at high-volume centers are higher, he said.

But many don't have access to a high-volume center. In those cases, he suggested they ask their doctor: "Do you follow NCCN guidelines?"

Data and conclusions presented at medical meetings are typically considered preliminary until published in a peer-reviewed medical journal.

More information: For more on the national guidelines for cancer treatment, visit the National Comprehensive Cancer Network.

Health News Copyright © 2013 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

New fluorescent tools for cancer diagnosis

In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...

Cancer created May 24, 2013 | popularity not rated yet | comments 0

Modulating the immune system to combat metastatic cancer

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...

Cancer created May 24, 2013 | popularity 5 / 5 (1) | comments 0

Scientists put bowel cancer under the microscope

Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.

Cancer created May 24, 2013 | popularity 5 / 5 (1) | comments 0

Researcher identifies breast cancer fighting hormone

Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.

Cancer created May 24, 2013 | popularity 5 / 5 (2) | comments 0

Ground breaking cancer research finds immune system link

(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.

Cancer created May 24, 2013 | popularity 5 / 5 (4) | comments 0


First drug to improve heart failure mortality in over a decade

Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...

Seniors more likely to crash when driving with pet, study finds

(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...

Heart failure accelerates male 'menopause'

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...

Death highest in heart failure patients admitted in January, on Friday, and overnight

Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...

Feds fight morning-after pill age ruling in NY

(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...

New immune system discovered

(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.